Skip to main content

Advertisement

SpringerLink
Log in

Genetics

Predictive value of KRAS mutations in chemoresistant CRC

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).

    Article  CAS  Google Scholar 

  2. Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004).

    Article  CAS  Google Scholar 

  3. Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040–2048 (2007).

    Article  CAS  Google Scholar 

  4. De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508–515 (2008).

    Article  CAS  Google Scholar 

  5. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).

    Article  CAS  Google Scholar 

  6. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626–1634 (2008).

    Article  CAS  Google Scholar 

  7. Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2009).

    Article  CAS  Google Scholar 

  8. Van Cutsem, E. et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [Abstract]. Proc. Am. Soc. Clin. Oncol. 26, 2 (2008).

    Article  Google Scholar 

  9. Etienne-Grimaldi, M. C. et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res. 14, 4830–4835 (2008).

    Article  CAS  Google Scholar 

  10. Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705–5712 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paris Descartes University Medical School, Paris, France

    Pierre Laurent-Puig

  2. INSERM laboratory, Paris, France

    Astrid Lièvre

Authors
  1. Astrid Lièvre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre Laurent-Puig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Laurent-Puig.

Ethics declarations

Competing interests

P. Laurent-Puig is a Consultant and receives grant/research support from Amgen and Merck. A. Lievre received grant/research support from Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lièvre, A., Laurent-Puig, P. Predictive value of KRAS mutations in chemoresistant CRC. Nat Rev Clin Oncol 6, 306–307 (2009). https://doi.org/10.1038/nrclinonc.2009.69

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.69

  • Springer Nature Limited

This article is cited by

Search

Navigation